To include your compound in the COVID-19 Resource Center, submit it here.

ODAC rejects Marqibo

FDA's Oncologic Drugs Advisory Committee voted unanimously against accelerated approval for Marqibo vincristine from Inex (TSE:IEX) and Enzon (ENZN) to treat

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE